【摘要】：背景和目的食道癌是全世界癌癥死亡的第六主要原因,在中國尤其常見[1]。然而,與西方國家和日本相比,我們遠遠落后于時代,貢獻最少的A級證據(jù)[2-3]。與其他胃腸道惡性腫瘤相比,食管癌由于早期淋巴結(jié)和遠處器官轉(zhuǎn)移而呈現(xiàn)出高度惡性。局部晚期或廣泛轉(zhuǎn)移食管癌因其嚴重侵襲周圍器官、進展迅速且患者因進食困難造成營養(yǎng)狀況差而難以治療繼而導致預后差[4-5]。相關(guān)文獻顯示食管癌患者的5年生存率僅為5%-30%[5]。以往,食管切除術(shù)在早期和局部食管癌治療中起著關(guān)鍵作用,但對于老年患者,食管切除術(shù)的應用卻日益減少[6-8],這是因為大多數(shù)患者在確診時已屬于晚期,失去了最佳手術(shù)機會[9]。過去的10到15年中已完成的臨床試驗表明,除了手術(shù)切除之外還存在一些可以提高晚期食管癌患者生存期的治療方案[10-11]�；瘜W治療,對食管癌患者來說起著十分重要的作用。一般而言,氟尿嘧啶聯(lián)合鉑類被視為晚期食管癌的標準一線化療方案,其反應率可達25%-45%[12-16],但中位生存期卻不到一年[17-19]。然而,大多數(shù)患者在標準一線化療后迅速發(fā)生轉(zhuǎn)移或復發(fā),隨后進行二線化療[20-22],但是研究發(fā)現(xiàn)二線化療療效遠不如一線化療。怎樣才能延長一線化療后疾病進展時間呢?對于那些在化療中獲益的患者的后續(xù)治療,過去曾經(jīng)采取“觀望并等待”的模式。但最近幾年,借鑒血液學腫瘤的成功治療模式[9],應用高效、低毒的單藥作為對實體腫瘤的維持治療已經(jīng)應用于晚期卵巢癌、晚期結(jié)直腸癌、晚期非小細胞肺癌、晚期胃癌、胰腺癌中,結(jié)果表明維持治療可延長疾病無進展生存期,甚至可能達到生存獲益[23-24]。但目前針對食管癌的維持治療卻較少報道�？ㄅ嗨麨I是一種口服氟尿嘧啶類藥物[25-27],相關(guān)試驗表明卡培他濱維持治療可延長晚期食管癌患者的無進展生存期和總生存期[28]。替吉奧(S-1)是一種口服復方氟尿嘧啶衍生物,最早由日本大鵬藥品工業(yè)株式會社研制,S-1是替加氟、吉美嘧啶和奧替拉西鉀的混合物,摩爾比為1:0.4:1[29-31]。替加氟是一種口服5-FU前體藥物;吉美嘧啶是二氫嘧啶脫氫酶抑制劑,可增強5-FU的作用;奧替拉西鉀可以減少5-FU的胃腸毒性。因此,從整個配方結(jié)構(gòu),S-1既可增強抗腫瘤作用,延長作用時間,同時也降低了胃腸道毒性[32-33]。到目前為止,S-1已被廣泛應用在各種癌癥中,如頭頸部癌,肺癌和胰腺癌等[34-36]。S-1與順鉑的聯(lián)合化療已被確立為胃癌的標準化療方案[37-39]。S-1用于胰腺癌、胃癌、結(jié)直腸癌等消化道腫瘤的維持治療在中外期刊上也見報道[40-41]。基于上述事實,我們有理由認為,對于食管癌患者,S-1是一個很有潛力的維持治療藥物。本研究通過對2012.01到2015.12的66例晚期食管癌患者應用S-1維持治療的臨床資料進行回顧性分析,探討S-1維持治療的臨床療效、不良反應。資料與方法研究對象為2012年1月1日—2015年12月31日鄭州大學第一附屬醫(yī)院腫瘤內(nèi)科收治的經(jīng)病理學確診為晚期食管癌的66例患者,既往均接受過順鉑聯(lián)合氟尿嘧啶方案一線化療4~6個周期后,療效評價為完全緩解、部分緩解或疾病穩(wěn)定,其中31例繼續(xù)接受S-1單藥口服維持治療直至疾病進展或出現(xiàn)不能耐受的不良反應(S-1維持治療組),另35例接受最佳支持治療(對照組)。觀察疾病反應率、疾病控制率、無進展生存期、總生存期及不良反應。統(tǒng)計學方法所有數(shù)據(jù)均采用SPSS17.0統(tǒng)計學軟件進行分析,分類資料采用χ2檢驗,生存分析采用Kaplan-Meier法。P0.05為差異有統(tǒng)計學意義。結(jié)果1.S-1維持治療組的客觀反應率為22.6%,優(yōu)于對照組的3.9%(P0.05)。2.S-1維持治療組的疾病控制率為38.7%,盡管高于對照組的22.9%,但差異無統(tǒng)計學意義(P0.05)。3.S-1維持治療組的中位無進展生存期為17.0個月,優(yōu)于對照組的10.0個月(P0.05)。4.S-1維持治療組的主要毒副反應為惡心、嘔吐、貧血、白細胞減少和手足綜合征等,經(jīng)對癥治療后均好轉(zhuǎn),無治療相關(guān)性死亡病例出現(xiàn)。結(jié)論一線治療后繼續(xù)替吉奧單藥維持治療晚期食管癌,可提高近期有效率,延長中位無進展生存期,不良反應可以耐受。
[Abstract]:Background and objective esophagus cancer is the sixth main cause of cancer death in the world. In China, [1]. is especially common, however, compared with the western countries and Japan, we are far behind the times. Compared to the other gastrointestinal malignancies, the least contribution of the A-level evidence, [2-3]., presents a high level of early lymph node and distant organ metastasis. Malignant. Locally advanced or widely metastatic carcinoma of the esophagus, due to its severe invasion of the peripheral organs, is progressing rapidly and the patient is poor in nutritional status due to the difficulty of eating. The poor prognosis of the patients leads to poor prognosis, [4-5]. related literature shows that the 5 year survival rate of esophageal cancer patients is only 5%-30%[5].. Esophagectomy has been used in early and local esophageal cancer treatment. There is a key role, but for elderly patients, the use of esophagectomy is increasingly reduced by [6-8], because most patients are late at the time of diagnosis and lose the best chance of operation, [9]. has completed the past 10 to 15 years of clinical trials showing that there are some patients with advanced esophageal cancer besides surgical excision. [10-11]. chemotherapy is very important for patients with esophageal cancer. Generally speaking, fluorouracil combined with platinum is considered as a standard first-line chemotherapy regimen for advanced esophageal cancer, with a response rate of up to 25%-45%[12-16], but the median survival time is less than one year [17-19]., but most of the patients are in the standard line. There is a rapid metastasis or recurrence after treatment, followed by a second line chemotherapy [20-22], but the study has found that second line chemotherapy is far less effective than first-line chemotherapy. How can we extend the time for disease progression after first-line chemotherapy? For patients who benefit from chemotherapy, follow-up treatment has been "wait-and-see" in the past, but in recent years, Using the successful treatment model [9] for hematological tumors, the application of high efficient, low toxic single drug as a maintenance therapy for solid tumors has been applied to advanced ovarian cancer, advanced colorectal cancer, advanced non-small cell lung cancer, advanced gastric cancer, and pancreatic cancer. The results indicate that maintenance treatment can not survive and even achieve survival benefit. [23-24]. but current treatment for esophageal cancer is less reported. Capecitabine is an oral fluorouracil drug [25-27]. Related trials suggest that capecitabine maintenance therapy prolongs the progression free survival of patients with advanced esophageal cancer and the total survival time [28]. teggio (S-1) is an oral compound fluorouracil derivative, the earliest S-1 is a mixture of tegafon, pyrimidine and oretirase, the mole ratio is 1:0.4:1[29-31]. tegafur, an oral 5-FU precursor drug; gimilacil is a two hydrogen pyrimidine dehydrogenase inhibitor, which can enhance the effect of 5-FU; thus, oretiari potassium can reduce the gastrointestinal toxicity of 5-FU. Therefore, from the whole, from the whole The combination of [34-36].S-1 and cisplatin, such as head and neck cancer, lung cancer and pancreatic cancer, has been widely used in various cancers, such as head and neck cancer, lung cancer and pancreatic cancer, and the combined chemotherapy of [34-36].S-1 and cisplatin, such as head and neck cancer, lung cancer and pancreatic cancer, has been established as the standard chemotherapy for gastric cancer, [37-39].S-1 is used in the pancreas for the use of S-1. The maintenance treatment of digestive tract tumors such as adenocarcinoma, gastric cancer and colorectal cancer is also reported in Chinese and foreign periodicals. [40-41]. is based on the above facts. We have reason to think that S-1 is a potential maintenance therapy for patients with esophageal cancer. This study is based on the application of S-1 maintenance therapy to 66 patients with advanced esophageal cancer in 2012.01 to 2015.12. The clinical efficacy and adverse reactions of S-1 maintenance treatment were analyzed retrospectively. 66 patients with advanced esophageal cancer confirmed by pathology from January 1, 2012 to December 31, 2015 in the First Affiliated Hospital of Zhengzhou University were treated with cisplatin combined with fluorouracil. After line chemotherapy for 4~6 cycles, the curative effect was evaluated as complete remission, partial remission or disease stability, of which 31 cases continued to accept S-1 single drug oral maintenance therapy until disease progression or intolerance (S-1 maintenance treatment group), and the other 35 cases received optimal support treatment (control group). The survival period, the total life period and the adverse reaction. All the statistical methods were analyzed by SPSS17.0 statistics software. The classification data were tested by chi 2, and the survival analysis using the Kaplan-Meier method.P0.05 was statistically significant. Results the objective response rate of the 1.S-1 maintenance group was 22.6%, which was better than the control group of 3.9% (P0.05).2.S-1 maintenance. The rate of disease control in the treatment group was 38.7%, although it was higher than 22.9% in the control group, but the difference was not statistically significant (P0.05) the median progression free survival of the.3.S-1 maintenance group was 17 months, and the major side effects of the 10 months (P0.05) group of the control group were nausea, vomiting, anemia, leukocyte reduction and hand foot syndrome. After treatment, there was no treatment related death cases. Conclusion after first-line treatment, continuing the treatment of advanced esophageal cancer with monotherapy, can improve the short-term efficiency, prolong the median progression free survival and tolerable adverse effects.
【學位授予單位】：鄭州大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.1

【相似文獻】

相關(guān)期刊論文 前10條

1 林少東;中西醫(yī)結(jié)合治療晚期食管癌疼痛臨床觀察[J];中國中醫(yī)急癥;2000年06期

2 王敏 ,郭進玉 ,莊玲 ,鄭芳 ,梁秀欽;帶膜記憶合金支架治療晚期食管癌18例報告[J];福建醫(yī)藥雜志;2003年01期

3 畢訊;宋杏麗;張金哲;;消瘤行治療晚期食管癌療效分析[J];中成藥;2008年09期

4 張春珍;王俊生;;晚期食管癌的化療進展[J];實用癌癥雜志;2008年06期

5 都振利;位春紅;王芳;;放化療聯(lián)合治療晚期食管癌的臨床觀察[J];腫瘤基礎(chǔ)與臨床;2010年05期

6 林彬;張軼;;放化療聯(lián)合治療晚期食管癌25例報告[J];山東醫(yī)藥;2010年50期

7 陳卓明;;晚期食管癌2種化療方案療效對比觀察[J];現(xiàn)代腫瘤醫(yī)學;2012年06期

8 劉少翔;侯浚;陳志峰;高良;張秀云;;中藥結(jié)合化療治療晚期食管癌60例療效觀察[J];河北中醫(yī);1993年03期

9 陳忠戶，，李瑞鋒，潘清輝;藥物與放射綜合治療晚期食管癌30例[J];福建醫(yī)藥雜志;1995年06期

10 王牧民,高舉富,裴志東;晚期食管癌綜合治療觀察[J];中國腫瘤臨床與康復;1997年02期

相關(guān)會議論文 前10條

1 趙東;;69例放化療治療中、晚期食管癌的臨床評價[A];中華醫(yī)學會放射腫瘤治療學分會六屆二次暨中國抗癌協(xié)會腫瘤放療專業(yè)委員會二屆二次學術(shù)會議論文集[C];2009年

2 樊青霞;張付紅;;晚期食管癌的化療進展[A];中國第九屆全國食管癌學術(shù)會議論文集[C];2009年

3 張集昌;張力建;;晚期食管癌伴食管癌性瘺的內(nèi)鏡姑息治療47例分析[A];第四屆中國腫瘤學術(shù)大會暨第五屆海峽兩岸腫瘤學術(shù)會議論文集[C];2006年

4 王敏;;“以毒攻毒”救治晚期食管癌[A];2011年中華名中醫(yī)論壇暨發(fā)揮中西醫(yī)優(yōu)勢防治腫瘤高峰論壇論文集[C];2011年

5 張駿;吳佩卿;張儉;;晚期食管癌支架植入術(shù)的并發(fā)癥及其防治[A];2004年浙江省胸心外科學術(shù)年會論文匯編[C];2004年

6 王長福;;內(nèi)鏡支架置入與深靜脈營養(yǎng)對晚期食管癌患者生存影響人前瞻性研究[A];第四屆中國腫瘤學術(shù)大會暨第五屆海峽兩岸腫瘤學術(shù)會議論文集[C];2006年

7 蔡玲;劉孟忠;陳爾成;胡永紅;李巧巧;劉慧;;同期放化療和單純放療治療局部晚期食管癌療效的配對分析[A];2007第六屆全國放射腫瘤學學術(shù)年會論文集[C];2007年

8 王洪州;文黎明;龔建輝;鄧麗娟;;~(125)碘種子源治療晚期食管癌的臨床研究[A];第二屆全國核素顯像及治療學術(shù)會議論文摘要匯編[C];2004年

9 朱芳來;凌安生;;胃鏡下微波燒灼聯(lián)合局部化療治療晚期食管癌[A];中華醫(yī)學會第七次全國消化病學術(shù)會議論文匯編（下冊）[C];2007年

10 朱文婷;程志強;;西黃丸聯(lián)合化療治療晚期食管癌18例臨床觀察[A];西黃丸臨床應用研究論文集[C];2009年

相關(guān)重要報紙文章 前10條

1 衣曉峰;晚期食管癌患者生存質(zhì)量提高[N];中國醫(yī)藥報;2004年

2 衣曉峰 李媛媛;食管內(nèi)安支架 近距離行放射[N];健康報;2005年

3 李俊 邢海英;吉奧：出戰(zhàn)意大利車展[N];人民政協(xié)報;2006年

4 萬州邋小波;標識,引發(fā)中德企業(yè)幾度訴訟[N];常州日報;2007年

5 王婭莉;吉奧商道行萬里[N];中國質(zhì)量報;2008年

6 邢海英;吉奧：品牌修煉再上層樓[N];人民政協(xié)報;2008年

7 錢立平;“吉奧”品牌修煉再創(chuàng)新榮譽[N];臺州日報;2008年

8 本報記者 丁楊;吉奧殺回國內(nèi)指望農(nóng)村成全[N];經(jīng)濟觀察報;2009年

9 劉國杰;吉奧文化給員工帶來精彩生活[N];中國現(xiàn)代企業(yè)報;2009年

10 本報實習記者 宋家婷;吉奧寄望“帥豹”提升品牌[N];中國商報;2009年

相關(guān)博士學位論文 前1條

1 劉德若;電化學對晚期食管癌的療效和作用機理的研究[D];中國協(xié)和醫(yī)科大學;1995年

相關(guān)碩士學位論文 前10條

1 張虹;晚期食管癌TP與FP方案化療的隨機對照以及ERCC1表達與含順鉑方案化療敏感性相關(guān)性研究[D];安徽醫(yī)科大學;2015年

2 姚藝瑋;ERCC1基因檢測指導晚期食管癌個體化治療的臨床研究[D];安徽醫(yī)科大學;2015年

3 樊t

本文編號：2137569